This article is a correction to:
Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
Ni Zhao1
Wen Cao
Xiao Fu
Chunli Li- 1Department of Medical Oncology, The First Affiliated Hospital of Xi’’an Jiaotong University, Xi’an, China
- 2Department of Respiratory Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
- 3Department of Hematology. The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
A Corrigendum on:
Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy.
By Zhao N, Yi Y, Cao W, Fu X, Mei N and Li C (2022) 12:923531. doi: 10.3389/fonc.2022.923531
In the published article, there was an error in the legend for Figure 12 and Figure 13 as published. There was a mistake in the legend for Figure 12 and Figure 13, an incorrect description was used.
FIGURE 12
Figure 12 (A) Differences in IL-6 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.
FIGURE 13
Figure 13 (A) Differences in IL-8 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.
“Figure 12. (A) Differences in IL-6 levels after the second cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.” should be “Figure 12. (A) Differences in IL-6 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.”
“Figure 13 (A) Differences in IL-8 levels after the second cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.” should be “Figure 13 (A) Differences in IL-8 levels after the third cycle therapy between CB and UCB; (B) The nomogram based on logistic multivariate analysis.”
The corrected legend appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
In the published article, there was an error in Figure 3 as published. “81 patients had not been treated for six months at the end of follow-up and could not be analyzed for effectiveness.” should be “79 patients had not been treated for six months at the end of follow-up and could not be analyzed for effectiveness.”
The corrected Figure 3 and its caption appear below.
FIGURE 3
Figure 3 Selection process for patients.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: biomarkers, cytokines, immunotherapy, lung cancer, immune related adverse events
Citation: Zhao N, Yi Y, Cao W, Fu X, Mei N and Li C (2022) Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. Front. Oncol. 12:1069999. doi: 10.3389/fonc.2022.1069999
Received: 14 October 2022; Accepted: 28 November 2022;
Published: 13 December 2022.
Edited and Reviewed by:
Jun Zhang, University of Kansas Medical Center, United StatesCopyright © 2022 Zhao, Yi, Cao, Fu, Mei and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chunli Li, chunli5158@163.com